
|Articles|October 17, 2012
Antibody may improve plaque psoriasis
A fully human monoclonal antibody that has been found to inhibit interleukin-17A may significantly improve moderate-to-severe plaque psoriasis, according to new phase 2 study data recently released.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
The Rx Recap: December 14-19
3
The Aesthetic Edge: December 2025
4
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
5

















